Over the last 7 days, the United States market has remained flat, yet it has experienced a notable 12% rise over the past year with earnings forecasted to grow by 15% annually. In such an environment, ...

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite outperforming the medical sector over the past month. Analysts eagerly await its ...

Alright, listen to me. This one is one that everyone’s going to give up on. Then one day, it’s going to be up 300, I’m not ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per ...